- Home
- SG vs MPLT Comparison
SG vs MPLT Comparison
Compare SG & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SG | MPLT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.3M | 811.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SG | MPLT |
|---|---|---|
| Price | $5.29 | $17.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $8.55 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 3.9M | 148.1K |
| Earning Date | 05-07-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $679,474,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $5.00 | $12.24 |
| 52 Week High | $27.15 | $21.55 |
Technical Indicators
Market Signals| Indicator | SG | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 46.50 |
| Support Level | $5.10 | $16.17 |
| Resistance Level | $6.16 | $20.20 |
| Average True Range (ATR) | 0.36 | 1.32 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 16.19 | 26.06 |
Price Performance
Historical ComparisonAbout SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.